With New $150M Headquarters, Astellas Seeks More Qualified Reps for US Sales Growth

June 6, 2012 - PRLog -- U.S. growth for Astellas helped account for the company’s 15.6% jump in net income during the year that ended March 31.  The U.S. is part of Astellas’ “Americas” region, which saw revenues rise 6.7% in the 2011–12 fiscal year to $2.32 billion—part of a total nearly $12.4 billion in total global sales—paced by sales of its urinary disorder treatment Vesicare and the anticancer treatment Tarceva.

With the new headquarters, based in Illinois, a new light has been shed on the need for industry trained pharmaceutical sales representatives. The National Association of Pharmaceutical Representatives® (NAPRx®) has developed the CNPR® Certification program to educate candidates so that they will be able to differentiate themselves from other candidates. The majority of entry level candidates do not know enough about the pharmaceutical industry, drug patents, FDA regulations, CDER regulations, laws governing the pharmaceutical industry, the anatomy, pharmaceutical terms and abbreviations, drug sampling rules, effective physician selling skills, pharmaceutical selling guidelines & regulations, managed care, etc.

Astellas is also stepping up U.S. drug discovery activity. Also today, the company announced it has entered into a second partnership to develop and commercialize an Astellas compound with Drais Pharmaceuticals. Astellas will transfer ownership of ASP7147, a treatment for irritable bowel syndrome with diarrhea, to Seldar Pharma, a virtual company that will be operated by the Drais executive team. The partnership is similar to one Astellas and Drais entered into in April to advance another compound through another virtual company.

To qualify for and apply to upcoming positions with Astellas and numerous other companies, visit the National Association of Pharmaceutical Representatives at www.napsronline.org.


www.napsronline.org
800-284-1060